
Dephos500 mg
Eskayef Bangladesh Ltd.
Sucroferric Oxyhydroxide is an iron-based, calcium-free phosphate binder with the following approved and guideline-supported uses: Established / FDA-Approved Use Control of serum phosphorus…
Sucroferric Oxyhydroxide is an iron-based, calcium-free phosphate binder with the following approved and guideline-supported uses:
Sucroferric Oxyhydroxide is intended for chronic, ongoing use alongside routine dialysis care and periodic laboratory monitoring, not as a stand-alone or short-course treatment.
| Population | Starting Dose | Titration |
|---|---|---|
| Adults and children ≥ 12 years on dialysis | One 500 mg tablet three times daily with meals (1500 mg/day) | Adjust by one tablet (500 mg) per day at intervals of one week or longer, based on serum phosphorus levels, up to a maximum studied dose of 3000 mg/day |
| Children 9 to less than 12 years on dialysis | One 500 mg tablet twice daily with meals (1000 mg/day) | Adjust under close physician supervision based on serum phosphorus response |
Dose should be individualized and titrated to achieve and maintain an acceptable serum phosphorus level, with regular monitoring by the treating nephrologist. See Use in Special Populations for pediatric and elderly considerations, and Interactions for dosing-separation advice with other oral medicines.
The most common side effects of Sucroferric Oxyhydroxide are gastrointestinal and generally mild to moderate:
Uncommon effects reported after marketing include tooth discoloration (typically reversible with dental hygiene) and skin rash. Patients should contact their physician if side effects are severe, persistent, or accompanied by other concerning symptoms.
Sucroferric Oxyhydroxide is contraindicated in patients with known hypersensitivity to Sucroferric Oxyhydroxide or any component of the formulation. No other absolute contraindications are established. Patients with conditions such as active peritonitis, significant hepatic or gastrointestinal disorders, iron-overload conditions (e.g., hemochromatosis), or recent major gastrointestinal surgery were excluded from clinical trials of Sucroferric Oxyhydroxide and require careful clinical judgment and monitoring rather than automatic exclusion — see Precautions and Warnings.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.